TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Bram Verstockt  1     Severine Vermeire  2     Britta Siegmund  3     Florian Rieder  4     Stefan Schreiber  5     Simon Lichtiger  6     Rebecca Mosig  6     Fabio Cataldi  6     Silvio Danese  7    
1 University Hospitals Leuven and KU Leuven, Translational Research in Gastrointestinal Disorders - IB, Leuven, Belgium
2 University Hospital Leuven, Leuven, Belgium
3 Charité - Universitätsmedizin Berlin, Berlin, Germany
4 Cleveland Clinic Foundation, Cleveland Heights, United States
5 University Hospital Schleswig-Holstein, Kiel, Germany
6 Landos Biopharma, Inc, Blacksburg, United States
7 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing